Incorporation of Simian Virus 5 Fusion Protein into Murine Leukemia Virus Particles and Its Effect on the Co-incorporation of Retroviral Envelope Glycoproteins  by Hatziioannou, Theodora et al.
Virology 267, 49–57 (2000)
doi:10.1006/viro.1999.0091, available online at http://www.idealibrary.com onIncorporation of Simian Virus 5 Fusion Protein into Murine Leukemia Virus Particles and
Its Effect on the Co-incorporation of Retroviral Envelope Glycoproteins
Theodora Hatziioannou,* Stephen J. Russell,† and Franc¸ois-Loı¨c Cosset*
*Laboratoire de Vectorologie Re´trovirale et The´rapie Ge´nique, Unite´ de Virologie Humaine, INSERM U412, Ecole Normale Supe´rieure de Lyon,
69364 Lyon Cedex 07, France; and †Molecular Medicine Program, Guggenheim 18, Mayo Clinic, Rochester, Minnesota 55905
Received July 6, 1999; returned to author for revision November 4, 1999; accepted November 17, 1999
We describe the generation of murine leukemia virus (MLV) virus particles carrying the paramyxovirus fusion protein F from
simian virus 5 (SV5-F). This glycoprotein was expressed in cells providing Moloney MLV (MoMLV) Gag and Pol proteins and
a lacZ retroviral vector. SV5-F was correctly expressed, processed, and efficiently incorporated into retroviral particles.
SV5-F-bearing retroviruses were not infectious although a weak binding to primate and rodent cells could be detected and
SV5-F could mediate cell to cell fusion. We then co-expressed the SV5-F glycoprotein in retroviral particles with chimeric and
wild-type MoMLV envelope glycoproteins. Our results show that F strongly inhibited infection via the retroviral envelopes
although the mechanism of inhibition was different depending on the retroviral envelope used. © 2000 Academic PressINTRODUCTION
Most retroviruses are thought to enter the target cells
by direct fusion of the viral particle at the cell surface
(McClure et al., 1990). Fusion is mediated by the enve-
lope glycoprotein of the retrovirus, which consists of two
subunits: the surface subunit (SU), comprising the recep-
tor binding domain, and the transmembrane subunit
(TM), comprising the membrane anchor and the fusion
peptide. Binding of the SU subunit to the cell surface
receptor induces conformational changes in the enve-
lope glycoprotein that lead to exposure of the fusion
peptide, normally buried within the envelope trimer, and
subsequent fusion of the viral and cell membranes. Like
retroviruses, paramyxoviruses are thought to fuse at the
cell surface (Lamb, 1993). In paramyxoviruses, however,
the binding and fusion functions are separated into two
different proteins, the attachment protein (generally hem-
agglutinin-neuraminidase (HN)) and the fusion protein F
(Lamb, 1993). The exact mechanism by which paramyxo-
viral fusion proteins are activated remains unknown.
Increasing evidence suggests that an interaction with
the homotypic attachment protein (HN for simian virus 5
(SV5)) is required to trigger their fusogenicity (Deng et al.,
1995; Yao et al., 1997). There are cases, however, such as
simian virus 5, where the F protein can mediate fusion in
the absence of HN (Horvath et al., 1992).
We show here that the F glycoprotein from SV5-F could
be efficiently incorporated into retroviral particles, yet the
hybrid viral particles were not infectious. We then co-
expressed SV5-F proteins with chimeric retroviral enve-
lope glycoproteins that retarget virion binding. Viral titers
obtained with viruses carrying these chimeras are gen-
49erally low, probably due to a number of problems, includ-
ing the poor fusogenicity of the chimeric glycoproteins
(Cosset and Russell, 1996). We therefore proceeded to
examine whether SV5-F could provide a helper fusion
function when co-expressed with our Moloney murine
leukemia virus (MoMLV)-based chimeric envelope glyco-
proteins and conversely whether the paramyxoviral at-
tachment protein could be replaced by a wild-type or
chimeric retroviral envelope glycoprotein in generating
infectious viral particles.
RESULTS
Efficient incorporation of paramyxovirus envelope gly-
coproteins into retroviral particles. The simian virus type
5 fusion (SV5-F) envelope glycoprotein (Fig. 1) was tran-
siently expressed in TELCeB6 cells (Cosset et al., 1995b)
that provide murine leukemia virus (MLV) retroviral core
particles and a lacZ retroviral vector. SV5-F was found to
be toxic to the cells and thus experiments were re-
stricted to transient expression.
The fusion protein of paramyxoviruses is synthesized
as a precursor, F0, subsequently cleaved by Golgi pro-
teases in the host cell into two disulfide-linked subunits,
F2 and F1. The simian virus 5 F protein forms trimers of
F2–F1 heterodimers (Russell et al., 1994). Western blots
on the lysates of SV5-F-transfected cells were performed
under nondenaturing conditions. Under these conditions
the F2–F1 trimers remain associated and thus a high-
molecular-weight band was obtained, migrating at about
205 kDa (Fig. 2A). The higher migrating bands observed
probably correspond to SV5-F protein aggregates. A
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50 HATZIIOANNOU, RUSSELL, AND COSSETfainter band, around 83 kDa, was also obtained and
probably corresponded to the SV5-F monomer (Fig. 2A).
To determine whether the SV5-F protein expressed
was incorporated into the retroviral particles, immuno-
blot analysis was performed on pellets obtained by ul-
tracentrifugation of supernatants of SV5-F-transfected
cells. SV5-F trimers were detected in the viral particles
pelleted from SV5-F-transfected TELCeB6 cells (Fig. 2A),
but not in pellets from SV5-F-transfected TElac2 cells,
which do not express Gag and Pol proteins (data not
shown). This demonstrated that SV5-F proteins detected
in pellets from TELCeB6 were associated with the retro-
viral particles. As a control, wild-type MLV envelope
expression plasmid was transiently transfected in TEL-
CeB6 cells. The MLV envelope glycoprotein is synthe-
sized as a precursor cleaved in the Golgi into the SU and
TM subunits. Two bands corresponding to the protein
precursor and the SU were observed in immunoblots of
cell lysates and in virion pellets (Fig. 2A). Relative to their
respective levels of expression in cells, the efficiency of
virion incorporation of SV5-F was slightly lower than that
of the wild-type MLV envelope glycoprotein (Fig. 2A).
Fusion activity of the SV5-F protein. We wanted to
FIG. 1. Schematic diagrams of envelope expression constructs.
cytomegalovirus (CMV) early promoter. Wild-type and chimeric retroviral
(LTR). The positions of some functional regions are indicated. Vertica
peptide. F2, N-terminal subunit of the SV5 fusion protein. F1, C-termin
wild-type and chimeric envelopes: SU, surface protein; TM, transmemb
domain; PiT-2, amphotropic MLV receptor binding domain; EGF, epiderm
boxes, MLV-A-derived env sequences; white boxes, other MLV-deriveddetermine whether the SV5-F protein expressed in TEL-
CeB6 cells was fusogenic. On certain target cells, suchas CV-1, SV5-F can induce the formation of syncytia
independent of the presence of SV5-HN (Horvath et al.,
1992). Therefore, to verify the biological activity of SV5-F,
cell to cell fusion assays were performed by co-cultivat-
ing CV-1 monkey or TE671 human indicator cells with
TELCeB6 cells expressing the wild-type SV5-F gene. As
expected, TELCeB6 cells that had been transfected with
only the SV5-F expression construct could form syncytia
with CV-1 indicator cells, although the syncytia were
larger and more numerous when SV5-HN was co-ex-
pressed with SV5-F (Table 1). A mutant of SV5-F, G3A
SV5-F (Horvath et al., 1992), with enhanced fusogenicity
was also expressed in TELCeB6 cells. The surface ex-
pression on TELCeB6 cells of both proteins was similar
(data not shown). However, the number of syncytia ob-
tained when cells expressing this mutant were co-culti-
vated with CV-1 cells was two times higher than when
the wild-type SV5 F-transfected cells were used (Table 1).
As expected, TELCeB6 cells expressing the combina-
tion of both SV5-F and SV5-HN could easily fuse the
TE671 indicator cells. However, in contrast to the obser-
vations with CV-1 indicator cells, no syncytia could be
obtained when TELCeB6 cells expressing SV5-F alone,
ian virus 5 fusion protein SV5-F was expressed with the human
pe glycoproteins were expressed with the MoMLV long terminal repeat
s, protein cleavage sites; T, transmembrane domain; SP, env signal
unit of the F protein comprising the transmembrane domain. MoMLV
otein; PRO, polyproline hinge; mCAT-1, ecotropic MLV receptor binding
wth factor: Dark gray boxes, MoMLV-derived env sequences; light gray
nces.The Sim
envelo
l arrow
al sub
rane prin the absence of SV5-HN, were co-cultivated with TE671
indicator cells (Table 1). Cells expressing the G3A SV5-F
51PSEUDOTYPING RETROVIRUSES WITH THE PARAMYXOVIRUS F PROTEINfusogenic mutant were also unable to produce syncytia
with TE671 cells (Table 1). Thus, although SV5-F was
fusion competent, its ability to mediate fusion in the
absence of SV5-HN depended on the nature of the target
cells.
Co-expression of SV5-F and recombinant MoMLV-de-
rived envelope glycoproteins into retroviral particles. To
determine whether SV5-F could promote virus–cell fu-
sion when co-expressed with heterologous attachment
proteins, we then co-expressed the SV5-F proteins with
chimeric retroviral envelope glycoproteins. Two retroviral
chimeras were used: EMO and AMO. EMO and AMO
(Fig. 1) are chimeric MoMLV-derived envelope glycopro-
teins designed to target the epidermal growth factor
(EGF) receptor or the PiT-2 phosphate transporter, re-
spectively (Cosset et al., 1995a). Such chimeras can
efficiently retarget the binding of retroviral particles onto
which they are inserted to their respective targeted re-
FIG. 2. Detection of envelope glycoproteins. (A) Immunoblots of
lysates of TELCeB6 cells nontransfected (2) or transiently transfected
(1) with the envelope glycoprotein indicated (depicted in Fig. 1) and of
pellets of viral particles produced from these cells. Blots were stained
with antibodies against the indicated proteins (see Materials and
Methods). (B) Detection of SV5-F glycoproteins after co-expression with
chimeric retroviral envelope glycoproteins. Immunoblots of pellets of
viral particles produced from SV5-F transfected TELCeB6 (T), T-EMO,
and T-AMO cells stained with anti-F antibody. For all of the immuno-
blots of virion pellets, the bottom panels (below 46 kDa) were stained
with anti-p30 antibodies to detect the p30-CA capsid protein (CA).ceptors, but cannot (EMO), or can barely (AMO), mediate
a retargeted infection (Cosset et al., 1995a).The SV5-F glycoprotein expression construct was tran-
siently transfected in T-AMO or T-EMO cells that stably
express MLV core particles, a lacZ retroviral vector, and
the AMO or the EMO chimeric retroviral envelope glyco-
proteins, respectively. Virions produced were analyzed
by immunoblotting. The levels of incorporation of SV5-F
in virions produced by SV5-F-transfected T-AMO or T-
EMO cells were comparable to those found in virions
produced by SV5-F-transfected TELCeB6 cells (Fig. 2B).
To further characterize the virions produced, superna-
tants of cells expressing EMO and/or SV5-F glycopro-
teins were incubated with A431 human cells, which over-
express EGF receptors. Binding of virions was then de-
tected using an anti-EGF antibody, shown previously to
reveal virion binding (Hatziioannou et al., 1998). Virions
generated with both EMO and SV5-F could bind A431
cells with a slightly lower efficiency than virions carrying
EMO alone (Fig. 3A). This suggested that F co-expres-
sion did not significantly affect the ability of virion-asso-
ciated EMO envelope glycoproteins to bind their target
EGF receptors.
Additionally a weak binding of virions carrying SV5 F
alone was revealed. This binding was also observed on
a number of other cell lines tested, including human
A431 cells and hamster Cerd9 cells (Fig. 3B). This bind-
ing could be due to the attachment of SV5 F to a yet
unidentified receptor. Alternatively it could be due to the
nonspecific attachment of F-carrying retroviral particles
to the cell surface.
Co-expression of SV5-F with MLV envelope glycopro-
teins decreases the infectivity of the produced virions.
Although retroviral particles carrying the SV5-F protein
alone appeared capable of binding to the different cell
lines tested, the infectious titers obtained with these
viruses were ,10 infectious units (iu)/ml on all the cell
lines tested such as Cerd9, A431, TE671, and CV-1 cells.
Subsequently the effect of SV5-F co-expression on the
infectivity of retroviruses carrying the chimeric retroviral
glycoproteins was studied.
TABLE 1
Cell to Cell Fusion Assays
Envelope
expressed
Target cells
CV-1 TE671
No env 2 2
SV5-F 1 2
SV5-F 1 SV5-HN 11 1
SV5-HN 2 2
G3A SV5-F 11 2
Note. TELCeB6 cells expressing the different surface proteins indi-
cated were co-cultivated with CV-1 or TE671 cells. Each plus sign
represents 200 syncytia/cm2.
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52 HATZIIOANNOU, RUSSELL, AND COSSETAs mentioned earlier, although chimeric envelope gly-
coproteins AMO and EMO efficiently retarget retrovirus
binding, the infectivity of these chimeric viruses is poor
(AMO viruses) to nonexistent (EMO viruses) (Cosset et
al., 1995a). In the case of AMO, the weak infectivity of the
etargeted retroviruses is due mainly to the low fusoge-
icity of the chimeric retroviral glycoproteins (Cosset and
ussell, 1996). Retroviruses carrying the chimeric AMO
nvelope glycoprotein can use the ecotropic virus recep-
or mCat-1 and/or the amphotropic receptor PiT-2 (Cos-
et et al., 1995a). Retroviruses were generated with PiT-
-targeting AMO envelopes alone or in combination with
he SV5-F glycoprotein and were used to infect PiT-2-
xpressing monkey CV-1 cells or human TE671 cells.
lthough retroviruses carrying AMO glycoproteins alone
ere infectious and had titers of 102 and 103 lacZ iu/ml
n CV-1 and TE671 cells, respectively, viruses carrying
oth AMO and SV5-F glycoproteins could not infect these
ells at all (Table 2). The same results were obtained
hen AMO was co-expressed with the highly fusogenic
3A SV5-F mutant glycoproteins (Table 2). The absence
f infectivity on CV-1 cells was particularly surprising
ince both the wild-type and the mutant SV5-F proteins
an mediate fusion of these cells, even in the absence of
FIG. 3. Virion binding assays. (A) EGF receptor-mediated binding a
Cell-bound virions were stained with anti-EGF monoclonal antibody. (B)
A431 (human), and CV-1 (monkey) cells. Cell-bound virions were stainhe paramyxoviral HN protein (Table 1).
Infection assays were also performed with retrovi-uses generated from producer cells co-expressing both
V5-F and EMO envelope glycoproteins. Binding of the
MO-carrying virions to the EGF receptors (EGFR) in-
uces virus sequestration, contributing to the lack of
nfectivity of these viruses (Cosset and Russell, 1996).
ence EMO-bearing viruses are unable to infect EGFR-
ositive cells (Cosset et al., 1995a). Retroviruses carrying
both EMO and SV5-F envelope glycoproteins could not
infect EGFR-positive A431 cells either, suggesting that
f virions coated with EMO or EMO 1 F glycoproteins on A431 cells.
assays of virions coated with SV5-F glycoproteins on Cerd9 (hamster),
the 1A anti-F mouse monoclonal antibody.
TABLE 2
Effect of SV5-F Expression on Infectivity of Viruses Produced from
Cells Expressing Retroviral Envelope Glycoproteins
Retroviral envelope expresseda
AMO EMO MO
Target cellsb CV-1 TE671 Cerd9 A431 Cerd9
2SV5-F 1 3 102 1 3 103 5 3 105 ,1 1 3 107
1SV5-F ,1 ,1 1 3 103 ,1 1 3 102
1G3A SV5-F ,1 ,1 nd nd nd
a SV5-F was transfected in cells expressing the indicated chimeric/
ild-type retroviral envelope glycoprotein.
bssays oViruses were titrated on the target cells indicated. Titers are re-
ported as lacZ iu/ml.
53PSEUDOTYPING RETROVIRUSES WITH THE PARAMYXOVIRUS F PROTEINSV5-F could not rescue the infectivity of virions bound to
EGF receptors (Table 2). Although they cannot infect
human cells that express EGF receptors, retroviruses
coated with EMO envelope glycoproteins can neverthe-
less easily infect EGF receptor-negative cells that ex-
press mCat-1 ecotropic receptors (Cosset et al., 1995a),
such as Cerd9 cells (Table 2). However, when infection
assays were performed on Cerd9 cells, retroviruses that
co-expressed both SV5-F and EMO glycoproteins had a
strongly reduced infectivity compared to retroviruses
generated with EMO envelopes alone by an order of
magnitude of up to 2–3 logs (Table 2).
To further investigate this inhibitory effect of SV5-F on
retroviral infection, we co-expressed SV5-F with the wild-
type Moloney envelope glycoprotein. The effect of SV5-F
co-expression on the infectivity of virions carrying wild-
type MoMLV envelopes was even greater than that ob-
served with the chimeric envelopes. Virions produced
when both proteins were co-expressed had titers 5 logs
lower than when the wild-type MoMLV glycoproteins
were expressed alone. This suggested that SV5-F had a
general fusion-inhibition activity when displayed on ret-
roviral particles together with heterologous attachment
glycoproteins.
Effect of SV5-F on incorporation of retroviral envelope
glycoproteins. To determine why SV5-F expression had
such an effect on the infectivity of virions when co-
expressed with chimeric or wild-type retroviral glycopro-
teins the virion incorporation of the retroviral envelopes
in the presence of SV5-F was analyzed. The presence of
SV5-F in the viral particle was confirmed by immunoblots
using the anti-F antibody (Fig. 4B).
Co-expression of SV5-F had no effect on the total
amount of EMO chimeric envelopes incorporated into
the virions produced; however, it did affect the process-
ing of the TM subunit of the chimeric envelope (Fig. 4A).
Similar results were obtained with the AMO envelopes
(data not shown). Retroviral envelope glycoproteins are
processed inside the virions by the viral protease, which
removes a 16-amino-acid peptide from the C-terminus of
the cytoplasmic tail, the R peptide. Removal of the R
peptide has been shown to be essential for the fusoge-
nicity of the envelope, and virions carrying nonprocessed
envelopes are poorly infectious (Rein et al., 1994).
The presence of unprocessed envelopes upon SV5-F
expression could account in part for the lower infectious
titers observed. The amount, however, of unprocessed
envelope, compared to that of the processed envelope,
is too low to explain the drastic decrease in infectious
titer obtained. Thus SV5-F must have other effects acting
at the level of viral entry, at a postbinding step.
On the other hand, co-expression of SV5-F had a
different effect on the wild-type MoMLV envelope glyco-
proteins in that it decreased dramatically their incorpo-
ration in the produced virions (Fig. 4A). It thus seems thatthe two envelopes compete for virion incorporation and
SV5-F is preferentially incorporated (Fig. 4B), excluding
the wild-type MoMLV envelopes. This “exclusion” ac-
counts for the decreased titers obtained when both pro-
teins are co-expressed. Similar results were obtained
with other wild-type envelopes such as the 4070A and
RD114 (data not shown).
DISCUSSION
Our results demonstrate that the fusion protein F from
simian virus 5 can be efficiently incorporated into MLV
particles, thus extending the list of nonretroviral glyco-
proteins incorporated into retroviral particles. The parti-
cles produced are not infectious despite a weak binding
observed on the surface of primate and rodent cells.
Furthermore, when SV5-F was coexpressed with retrovi-
ral envelope glycoproteins, it exhibited a strong inhibi-
tory effect on the infectivity of the produced virions. This
inhibition was due to different effects depending on the
nature of the retroviral envelope glycoprotein. In the case
of wild-type envelope glycoproteins, SV5-F competed
with the retroviral envelope for virion incorporation and
excluded the latter from being incorporated. The lower
level of incorporation of wild-type envelope glycopro-
FIG. 4. Effect of SV5-F on virion incorporation of retroviral envelope
glycoproteins. (A) Staining of retroviral glycoproteins. Immunoblots of
pellets of viral particles from cells stably expressing wild-type MoMLV
envelope glycoproteins (MO) or EMO chimeric envelope glycoproteins
(EMO), transfected (1) or not (2) with the SV5-F expression plasmid.
Staining was performed with antibodies against different retroviral
proteins as indicated. (B) Staining of SV5-F proteins. Viral pellets were
also run on a nondenaturing gel and stained with the anti-F monoclonal
antibody.teins, in the presence of SV5-F, was not due to their lower
expression levels in the cell (data not shown). Thus
54 HATZIIOANNOU, RUSSELL, AND COSSETSV5-F interferes with retroviral envelope incorporation
during budding.
The exact mechanism of envelope incorporation in
retroviral particles remains poorly defined. A specific
interaction between the envelope glycoproteins and the
Gag-Pol core has been suggested from studies on po-
larized cells (Lodge et al., 1997; Weclewicz et al., 1998).
Studies on HIV-1 show that the envelope glycoprotein
specifically interacts with the matrix protein of the Gag-
Pol precursor via its cytoplasmic tail (Cosson, 1996) but
no similar protein–protein interactions have been re-
ported for MLV. MLV virions have been shown to effi-
ciently incorporate envelope glycoproteins from other
viruses such as vesicular stomatitis virus (Emi et al.,
1991), Rous sarcoma virus (Landau and Littman, 1992),
Semliki Forest virus (Suomalainen and Garoff, 1994), hu-
man T-lymphotropic virus type 1 (Denesvre et al., 1996),
human foamy virus (Lindemann et al., 1997), fowl plaque
virus (Hatziioannou et al., 1998), Ebola virus (Wool-Lewis
and Bates, 1998), and HIV after truncation of the enve-
lope glycoprotein cytoplasmic domain (Mammano et al.,
1997; Schnierle et al., 1996). In these studies co-expres-
sion of the foreign glycoproteins with wild-type MLV was
not examined. A more recent report demonstrated that
the F protein from Sendai virus (paramyxovirus family)
can also pseudotype retroviral particles and when co-
expressed with a wild-type ecotropic retroviral envelope
it reduced the infectivity of the virions produced (Spiegel
et al., 1998). Furthermore we have also obtained the
same results when using the fusion protein from another
member of the paramyxovirus family, the measles virus F
protein (Hatziioannou and Cosset, unpublished data).
Thus the inhibitory effect on the infectivity via retroviral
envelope glycoproteins appears to be a common feature
among F proteins from different paramyxoviruses.
The mechanism of exclusion by F is not clear, partic-
ularly since this effect is not observed when chimeric
retroviral envelope glycoproteins are used. What we can
conclude from our data is that the primary amino acid
sequence of the cytoplasmic tail does not play a signif-
icant role during this process. Indeed the entire trans-
membrane subunit, comprising the cytoplasmic tail, of
the chimeric retroviral glycoproteins AMO and EMO is
identical to that of the wild-type MO envelope glycopro-
tein, yet the former are not excluded from the retroviral
particles in the presence of SV5-F. The only difference
between the chimeras and the wild-type envelope is that
the former have an additional binding domain. It is likely
that this addition influences the overall structure of the
chimeras compared to the wild-type glycoproteins, ren-
dering them more “resistant” to virion exclusion via F.
On the other hand, our data demonstrate that the SV5
fusion protein F is not fusion-active in the context of a
retroviral particle. Although the fusion-triggering activity
of paramyxovirus F proteins has not been clearly defined,two activation mechanisms have been proposed (Lamb,
1993). In the first model, the attachment protein HN
brings F close to the target cell membrane where F can
then mediate fusion either by recognition of an uniden-
tified cell surface receptor or simply by contact with the
target membrane. According to this model it should be
feasible to replace the paramyxovirus HN by another
attachment protein, such as a chimeric retroviral enve-
lope glycoprotein. However, our data indicate that SV5-F
cannot be functionally complemented by a retroviral at-
tachment glycoprotein, at least in the context of a retro-
viral particle. Our data are therefore consistent with the
second model of paramyxovirus F protein activation in
which there is a physical interaction between HN and F,
after HN has bound to its receptor, and this interaction
activates F. A physical association between homotypic
HN and F glycoproteins has been demonstrated for cer-
tain paramyxoviruses, suggesting that a highly specific
interaction between the two proteins is required for F to
be fusion active (Deng et al., 1995). Therefore, in the
absence of the corresponding HN to render F in its
fusion active state, F may remain in a rigid conformation,
behaving like a shield at the surface of the retroviral
particle that prevents the close approximation of viral
and cellular lipid membranes. However, other mecha-
nisms for the inhibitory effect of SV5-F in the context of a
retroviral envelope can be envisaged. For example, the F
trimers could sterically hinder the conformational rear-
rangements of the retroviral envelope required for fusion
to occur after receptor binding. Additionally they might
interfere with the lateral mobility of the retroviral enve-
lope proteins, thereby preventing them from clustering
into a fusion pore. Alternatively, binding of F to the target
cell surface might impede the mobility of the retroviral
receptors, shown to be important for retroviral fusion.
Finally our data do not exclude the unlikely possibility
that SV5-F and retroviral glycoproteins may form non-
functional mixed heterotrimers. In any case, this inhibi-
tory effect appears to be specific for the paramyxoviral F
protein since co-expression of the FPV (orthomyxovirus)
HA protein with certain chimeric retroviral envelopes
increased the infectivity of the virions produced com-
pared to the infectivity of viruses carrying either protein
alone (Hatziioannou et al., 1998).
Although co-expression of both SV5-F and SV5-HN
allowed the producer cells to fuse with target cells, the
virions produced from these cells were not infectious
(data not shown). Similar results were obtained with the
surface proteins from measles virus (Hatziioannou and
Cosset, unpublished data). In contrast Spiegel et al.
(1998), showed that infection of an ecotropic packaging
cell line with Sendai virus results in production of viruses
exhibiting the Sendai virus tropism. This result suggests
that both HN and F from Sendai virus are co-incorpo-
rated on the retroviral particle. However, it does not
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55PSEUDOTYPING RETROVIRUSES WITH THE PARAMYXOVIRUS F PROTEINexclude the possibility that other Sendai virus proteins
might also be associated with the retroviral particles and
contribute to their infectivity. Comparison between mem-
bers of the paramyxovirus family has demonstrated in
the past that different viruses have distinct requirements
to mediate fusion (Bagai and Lamb, 1995). Expression of
the paramyxovirus proteins in the context of retroviral
particles might allow a better identification of the viral
components required for the different paramyxoviruses
to mediate virus to cell fusion.
MATERIALS AND METHODS
Cell lines. The TELCeB6 cell line (Cosset et al., 1995b)
was derived from TELac2 (Takeuchi et al., 1994) after
ransfection and clonal selection of TE671 cells contain-
ng a plasmid expressing MoMLV gag and pol proteins.
ELCeB6 cells produce noninfectious viral core parti-
les, carrying an nlsLacZ reporter retroviral vector,
hereas TELac2 cells express only the nlsLacZ reporter
etroviral vector. T-EMO and T-AMO cells were derived
rom TELCeB6 cells that were stably transfected as pre-
iously described (Cosset et al., 1995a) by plasmids
expressing the EMO and the AMO chimeric envelope
glycoproteins, respectively, and were further enriched by
FACS cell sorting using anti-EGF (for EMO) or anti-gp70
(for AMO) antibodies.
TE671 (ATCC CRL8805) and A431 (ATCC CRL1555)
human cells and CV-1 African green monkey kidney cells
(ATCC CCL-70) were grown in DMEM (Life Technologies)
supplemented with 10% fetal bovine serum (Gibco BRL).
Cerd9 (Kozak et al., 1995) are derived from Chinese
hamster ovary cells (ATCC CCL-61) and express the
ecotropic MLV receptor (kind gift of D. Kabat). Cerd9 cells
were grown in DMEM (Life Technologies) supplemented
with 10% fetal bovine serum and with proline (Life Tech-
nologies).
Plasmids, transfection, and virus production. Plasmids
encoding the EMO and AMO chimeric envelopes were
described elsewhere (Cosset et al., 1995a). Briefly, AMO
consists of the Ram-1 binding polypeptide, provided by
the first 208 amino acids of the MLV-A SU, fused at codon
7 of the MoMLV SU. EMO was constructed by inserting
the sequence coding for EGF at the position correspond-
ing to amino acid 7 of the MoMLV SU. The two binding
domains carried by each chimeric envelope were sepa-
rated from the wild-type receptor binding domain by a
small linker containing three alanines. Both plasmids
contain the phleomycin-selectable marker (Fig. 1). Wild-
type and chimeric retroviral envelope glycoproteins were
expressed using the MoMLV long terminal repeat pro-
moter.
The SV5-F simian virus type 5 wild-type and G3A
mutant (Horvath et al., 1992) fusion glycoproteins (SV5-F
and G3A SV5-F, kindly provided by R. Lamb) and theSV5-HN simian virus type 5 hemagglutinin-neuramini-
dase glycoprotein (SV5-HN, kindly provided by R. Lamb)
were expressed using the hCMV-G (Yee et al., 1994)
xpression vector (after excision of the VSV-G gene)
nder control of the human cytomegalovirus early pro-
oter and rabbit b-globin intron sequences (Fig. 1).
Envelope glycoprotein expression plasmids were
transfected by calcium phosphate precipitation into TEL-
CeB6 cells as previously described (Cosset et al., 1995a).
Transfected cells were grown for about 48 h and virus-
containing supernatants were collected after an over-
night production from freshly confluent env-transfected
TELCeB6 cells in regular medium.
Antibodies. Antibodies used included the following:
anti-gp70 (Quality Biotech Inc., USA), a goat antiserum
raised against the Rausher leukemia virus gp(SU)70,
used diluted 1/2000 for Western blots; anti-CA (Quality
Biotech Inc.), a goat antiserum raised against the
Rausher leukemia virus p30 capsid protein (CA), used
diluted 1/10,000 for Western blots; anti-TM antibody (a
kind gift of Dr. A. Rein), which detects the transmem-
brane subunit of the MLV envelope glycoprotein, used
diluted 1/1000 for Western blots; anti-EGF 3D3 (Boehr-
inger Manheim), a mouse monoclonal antibody raised
against EGF, used diluted 1/100 for FACS analysis; and
anti-SV5-F (kindly provided by R. Lamb), a mouse mono-
clonal antibody 1A ascites fluid against SV5-F, used in
FACS analysis, diluted 1/2000, and an anti-F2 peptide
abbit serum used for Western blots, diluted 1/500.
Immunoblots. Virus producer cells were lysed in a 20
M Tris–HCl buffer (pH 7.5) containing 1% Triton X-100,
.05% SDS, 5 mg/ml sodium deoxycholate, 150 mM NaCl,
nd 1 mM PMSF. Lysates were incubated for 10 min at
°C and were centrifuged for 10 min at 10,000 g to pellet
he nuclei. Supernatants were then frozen at 270°C until
urther analysis. Virus samples were obtained by ultra-
entrifugation of viral supernatants (5 ml) in a SW41
eckman rotor (30,000 rpm, 1 h, 4°C). Pellets were sus-
ended in 50 ml of PBS (phosphate-buffered saline) and
frozen at 270°C. Samples (30 mg for cell lysates or 20 ml
for purified viruses) were mixed 5:1 (vol:vol) in a 375 mM
Tris–HCl (pH 6.8) buffer containing 6% SDS, 30% b-mer-
captoethanol, 10% glycerol, and 0.06% bromophenol
blue, boiled for 3 min, and then run on 10% SDS acryl-
amide gels. For nonreducing gels the b-mercaptoethanol
was omitted from the loading buffer, the samples were
not boiled, the percentage SDS of the gel was reduced
by half, and protein transfer onto nitrocellulose mem-
branes was performed in the absence of methanol from
the transfer buffer. After protein transfer onto nitrocellu-
lose filters, immunostaining was performed in TBS (Tris
base saline, pH 7.4) with 5% milk powder and 0.1%
Tween. The blots were probed with the relevant antibody
and developed using HRPO-conjugated Ig (immuno-
globulins) raised against the species of each primary
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56 HATZIIOANNOU, RUSSELL, AND COSSETantibody (Dako, UK) and using an enhanced chemilumi-
nescence kit (Amersham Life Science).
Binding assays. Target cells were washed in PBS and
detached by a 10-min incubation at 37°C with 0.02%
versene in PBS. Cells were washed in PBA (PBS with 2%
FCS and 0.1% sodium azide). A total of 5 3 105 cells were
incubated with virus supernatant for 45 min at 37°C for F
binding and at 4°C for EGF binding, in the presence of
polybrene (5 mg/ml). Cells were then washed with PBA
nd were incubated with the anti-F 1A antibody or the
nti-EGF antibody, respectively, for 45 min at 4°C. Cells
ere washed twice with PBA and incubated with anti-
ouse Ig FITC-conjugated antibodies (Dako). Five min-
tes before the two final washes in PBA, cells were
ounterstained with 20 mg/ml propidium iodide. Fluores-
ence of living cells was analyzed with a fluorescence-
ctivated cell sorter (FACSCalibur, Beckton Dickinson).
Cell–cell fusion assays. Transfected cells were de-
ached, counted, and reseeded at the same concentra-
ion (3 3 105 cells/plate) in six-well plates. Fresh CV-1 or
E671 cells (1 3 106 cells per well) were then added to
the transfected cells and were co-cultivated for 24 h. The
co-culture was stained by adding the May-Grunwald and
Giemsa solutions (Merck) according to the manufactur-
er’s recommendations.
Infection assays. Target cells were seeded in 24 mul-
tiwell plates at a density of 5 3 104 cells per well. Viral
supernatant dilutions containing 5 mg/ml polybrene were
added and cells were incubated for 3–5 h at 37°C. Viral
supernatant was then removed and cells were incubated
in regular medium for 48 h. X-Gal staining and viral titer
determination were performed as previously described
(Cosset et al., 1995a) as lacZ iu/ml.
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